Pfizer Aktie News

PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free...

Expand NYSE: PFE Pfizer Today's Change (-3.40%) $-0.90 Current Price $25.53 Key Data Points Market Cap $150B Day's Range $24.92 - $26.50 52wk Range $20.91 - $27.69 Volume 112M Avg Vol 68M Gross Margin 69.12% Dividend Yield 6.51% Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 ...

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.

Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.

Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions.

The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.

Pfizer expects revenue and earnings to fall in 2026.